CD80 and cancer: It remains unclear whether a shift to pro-inflammatory states would similarly be observed within TAM populations from RMC tumors treated using immunotherapy targeting the classical PD-L1/2 or CD80/86 immune checkpoint regulators, which appear relatively absent in this cancer type.